Mirtazapine (Remeron)
What studies of Mirtazapine (Remeron) found
At a glance, by condition
ME/CFS: C Might help, very uncertain
Based on the strongest evidence, the placebo trial (very low certainty): 3 findings, all C.
4 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Mirtazapine (Remeron) might help some people with ME/CFS, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Mirtazapine (Remeron) · ME/CFS is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
ME/CFS
Symptoms
Depression1 study · 36 people took Mirtazapine (Remeron) Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (72 in all).
The placebo trial72 randomised · mirtazapine 24 weeks; CCBT 12 weeks · standard dose 15– 45 mg, allowing lower dose, 24 weeks
Depression improved more than in the comparison group.
The evidence is very uncertain about the effect of mirtazapine (Remeron) on depression in ME/CFS. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (72 in all)
See the 1 study
-
- People in the study
- 72 randomised
- Dose
- standard dose 15– 45 mg, allowing lower dose, 24 weeks
- Outcome
- HRSD score Hamilton Rating Scale for Depression
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Low
Fatigue1 study · 36 people took Mirtazapine (Remeron) Uncertain –
Why this grade: Uncertain, moderate certainty, from randomised trials: few people (72 in all); helped less than ccbt, an active treatment; not a sign of harm.
The placebo trial72 randomised · mirtazapine 24 weeks; CCBT 12 weeks · standard dose 15– 45 mg, allowing lower dose, 24 weeks
Fatigue improved less than with the comparison treatment.
Mirtazapine (Remeron) helped fatigue less than ccbt in the one comparison. Uncertain · moderate certainty –
- Few people (72 in all)
- Helped less than ccbt, an active treatment; not a sign of harm
See the 1 study
-
- People in the study
- 72 randomised
- Dose
- standard dose 15– 45 mg, allowing lower dose, 24 weeks
- Outcome
- Fatigue Scale score Fatigue Scale
- Effect
- worse
- Risk of bias
RoB 2: Low
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Low
Daily life and health overall
Overall symptoms1 study · 36 people took Mirtazapine (Remeron) Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (72 in all).
The placebo trial72 randomised · mirtazapine 24 weeks; CCBT 12 weeks · standard dose 15– 45 mg, allowing lower dose, 24 weeks
Overall symptoms improved more than in the comparison group.
The evidence is very uncertain about the effect of mirtazapine (Remeron) on overall symptoms in ME/CFS. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (72 in all)
See the 1 study
-
- People in the study
- 72 randomised
- Dose
- standard dose 15– 45 mg, allowing lower dose, 24 weeks
- Outcome
- Clinical Global Impression Scale Clinical Global Impression
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Low
Quality of life1 study · 36 people took Mirtazapine (Remeron) Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (72 in all); effect size 0.99 (large).
The placebo trial72 randomised · mirtazapine 24 weeks; CCBT 12 weeks · standard dose 15– 45 mg, allowing lower dose, 24 weeks
Quality of life improved more than in the comparison group.
The evidence is very uncertain about the effect of mirtazapine (Remeron) on quality of life in ME/CFS. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (72 in all)
- Effect size 0.99 (large)
How big was the difference?
0.99, large. The effect size compares Mirtazapine (Remeron) with placebo.
See the 1 study
-
- People in the study
- 72 randomised
- Dose
- standard dose 15– 45 mg, allowing lower dose, 24 weeks
- Outcome
- SF–36 mental sub-scale 36-item Short Form Health Survey
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Low
Side effects
Side effects studies reported1 kind
| Side effect | Studies that reported it |
|---|---|
| Nausea or stomach upset | 1 study |
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
15 mg at the start
- 2Raise
Raised step by step in 1 of 1 studies
- 3Top dose
Most often 45 mg (1 of 1 studies)
Doses across 1 study
15 to 45 mg.
Each study’s dose, as printed
- standard dose 15– 45 mg, allowing lower dose, 24 weeks Cognitive-behavioural therapy v. mirtazapine for chronic fatigue and neurasthenia: randomised placebo-controlled trial. (2008)
All papers
- Cognitive-behavioural therapy v. mirtazapine for chronic fatigue and neurasthenia: randomised placebo-controlled trial.2008 · placebo trial · 72 randomised
Summary
This three-armed randomised clinical trial included 72 patients with chronic fatigue complaints; 65 of the 72 fulfilled Oxford criteria and 29 fulfilled CDC criteria. Participants were recruited at a specialist clinic, partly by general-practitioner referral and partly by screening. The study compared a comprehensive cognitive–behavioural treatment (CCBT) programme for 12 weeks (two 1.5 h group sessions per week: cognitive–behavioural therapy 1.5 h and body awareness therapy 1.5 h, plus a self-managed exercise programme) with double-blind mirtazapine (standard dose 15–45 mg, allowing lower dose) or inactive placebo. After 12 weeks, treatment continued for another 12 weeks in a mixed crossover–combination design. Primary outcomes were the Fatigue Scale and Clinical Global Impression (CGI); secondary measures included the Hamilton Rating Scale for Depression (HRSD), Subjective Health Complaint inventory (SHC), 36-item Short Form Health Survey (SF–36) and cardiorespiratory fitness. At 12 weeks, the CCBT group showed significant improvement compared with the mirtazapine and placebo groups on the Fatigue Scale (P=0.014) and CGI (P=0.001). At 24 weeks, the group initially receiving CCBT followed by mirtazapine showed significant improvement compared with the placebo-plus-CCBT reference group on the Fatigue Scale (P50.001), CGI (P=0.002), HRSD (P=0.018) and SHC pseudoneurology sub-scale (P=0.011). The SF–36 mental sub-scale showed significant improvement for mirtazapine for 24 weeks plus CCBT for 12 weeks (P=0.045). Secondary outcome measures showed overall improvement with no significant difference between treatment groups. All patients taking mirtazapine and 45% of patients taking placebo reported at least one adverse event. In the mirtazapine group, sedation was 56%, increased appetite 31%, weight increase 33% and restless legs syndrome 19%; in the placebo group, headache 17%, sedation 11%, weight increase 11% and insomnia 11%. Harms withdrawal counts are not reported.
- Intra-nasal esketamine induced psychotic disorder in a post COVID-19 major depressive episode: A case report.2024 · case report · 1 in the study
- Depression and brain fog as long-COVID mental health consequences: Difficult, complex and partially successful treatment of a 72-year-old patient-A case report.2023 · case report · 1 in the study
Summary
This case report describes one 72-year-old female with long COVID after COVID-19 infection, treated in a neurological day hospital and a psychiatric inpatient unit and followed as an outpatient. There was no comparison group. Between June 17 and July 8 2022 she was treated in a neurological day hospital without improvement in her health status. She then received outpatient psychiatric help and antidepressant therapy with sertraline 50 mg per day and mirtazapine 15 mg per day for almost 2 months, without significant improvement in her condition. In the psychiatric inpatient unit, between August 29 and September 23, 2022, she received venlafaxine up to 75 mg per day, trazodone up to 50 mg in the evening, nutritional supplements, enteral feeding, and non-drug therapy (visual art, music, drama, dance and movement therapy, occupational therapy, psychotherapy, physiotherapy). At hospitalization, PHQ-9 was 21 and CGI-S was 6; at discharge PHQ-9 was 8, CGI-S 3, and CGI-I 2. At the last outpatient follow-up visit on 01/5/2023, PHQ-9 was 5, CGI-S 3, and CGI-I 2. Mood, energy, anxiety, and sleep improved, but rapid fatigability, difficulty concentrating, unclear thinking, forgetfulness, and brain fog persisted; weight remained 48 kg with no weight gain, and she remained unable to resume work. Side effects and withdrawals were not reported.
- Treating chronic fatigue syndrome - a study into the scientific evidence for pharmacological treatments.2011 · review
Summary
The paper reports a questionnaire survey of 94 CFS patients from Queensland and New South Wales, recruited through support groups and newspaper and email advertisements, plus a search for randomised controlled trials. Patients filled out a questionnaire on current medicines and supplements; no treatment was given by the authors, and the survey had no comparison group. The 94 patients used 474 different medicines and supplements. Commonly used were antidepressants (41%), sedatives (27%), B vitamins (47%), magnesium (24%) and co-enzyme Q10 (7%). The search identified 20 RCTs. Findings included no difference for fluoxetine on fatigue or SF-36, no difference between treatment and placebo on individual questionnaires, and no effect for several agents including phenelzine, moclobemide, valaciclovir, terfenadine, melatonin, ginseng, bovine liver extract and a polynutrient supplement. One hydrocortisone trial reported 87% rated themselves improved versus 17% on placebo (p<0.001); another reported 53% vs. 29% (p=0.04) improvement in wellness score. Harm notes included diarrhoea with high-dose oral magnesium, long-term adrenal gland suppression with adrenal hormones, addiction and loss of effectiveness with benzodiazepines and opiates, and hormonal/lipid changes with DHEA. No worsening or stopping was reported. The authors state limitations.
- Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants.2009 · review
Summary
This review did not run its own trial; it summarized published data on pharmacological treatment of chronic fatigue syndrome (CFS), identified through a PubMed literature search. The review covers antidepressants and other psychotropic agents in CFS. In included randomized, placebo-controlled trials, moclobemide vs. placebo (47 vs. 43) showed clinically global improvement 51 vs. 33% (OR = 2.16); KPI mean difference between two groups was 0.28 favoring MCB, and Vigor subscale on POMS mean difference was 0.51 favoring MCB. Overall response by subjective global impression was 51% with moclobemide vs. 23% with placebo. At 12 weeks, MIR failed to separate from PBO on FS; at 24 weeks, CBT + MIR showed significantly more reduction in FS scores than PBO + CBT, with an observed difference of 5.5 (95% CI = 15.4 – 22), whereas MIR + CBT failed to separate from PBO + CBT. Fluoxetine failed to separate from PBO on SFS and BDI scores, and failed to demonstrate benefit on listed outcome measures. The review lists harms: TCAs potentially induce sedation and orthostatic hypotension; MAOIs have hypertensive crisis; stimulant medications carry risks of misuse, abuse, withdrawal, and diversion. Authors state research does not support definitive conclusions about antidepressant efficacy in CFS.